In Follow Up
Maritime-1
In Follow Up, Weight Loss
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight…
Pfizer Obesity
Weight Loss, In Follow Up
This study is looking at a once daily pill (PF-07976016) in combination with Liraglutide which is an approved GLP-1R agonist in patients…
MUIR-3
In Follow Up, High Triglyceride
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia…
Kardia-3
In Follow Up, Hypertension
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and…
Redefine-3
In Follow Up, Weight Loss
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with…
Shasta-4
In Follow Up, High Triglyceride
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe…
Triumph
In Follow Up, Weight Loss
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and chronic…
V-Prevent
In Follow Up, Cholesterol
The purpose of this study is to evaluate inclisiran sodium 300 mg s.c. (equivalent to 284 mg inclisiran) compared to placebo on reducing the…
Synchronize
In Follow Up
The purpose of this study is to find out whether people with overweight or obesity who take a medicine called survodutide (BI 456906) are…
Merck Cholesterol
In Follow Up, Cholesterol
The goal of this study is to evaluate the efficacy, safety, and tolerability of MK-0616 in adult participants with hypercholesterolemia. The…
Achieve-4-GZGS
In Follow Up, Diabetes
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type…
Oceanic (a)
In Follow Up, Lipoprotein (a)
The primary objective of this study is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease…